ACPU
TEVA icon

Arrowgrass Capital Partners (US)’s Teva Pharmaceuticals TEVA Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-551,600
Closed -$10.5M – 434
2017
Q4 		$10.5M Buy
551,600
+546,084
+9,900% +$8.21M 0.1% 218
2017
Q3 		$9.71M Buy
5,516
+700
+15% +$15.8K 0.07% 284
2017
Q2 		$16M Buy
4,816
+1,192
+33% +$36.9K 0.12% 219
2017
Q1 		$11.6M Buy
+3,624
New +$124K 0.12% 222

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s TEVA Position: Q1 2018 in Review

Arrowgrass Capital Partners (US) sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 885,401 shares — an estimated $16.8M sold.

Arrowgrass Capital Partners (US) first reported a position in TEVA in Q1 2016 and held it in 5 quarters. The position peaked at $16.8M in Q4 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 885,401 Teva Pharmaceuticals shares in Q1 2018, an estimated $16.8M.
  • Arrowgrass Capital Partners (US) first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Arrowgrass Capital Partners (US)'s Teva Pharmaceuticals position peaked at $16.8M in Q4 2017.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q1 2018, filed 15 May 2018.